HelixBind, Inc

HelixBind, Inc. is a biotechnology company based in Boxborough, Massachusetts, dedicated to developing innovative diagnostic platforms for detecting and managing invasive bloodstream infections, particularly sepsis. The company’s core technology is the patent-pending Pathogen Identification (PID) platform, which allows for rapid detection of bloodstream infections from whole blood samples, significantly reducing the time-to-diagnosis from days to hours. The RaPID/BSI Diagnostic Platform is a fully automated test that identifies bloodstream infections directly from blood samples, making it suitable for hospital use and adaptable for other clinical settings. The RaPID Sepsis Test, which has received Breakthrough Device Designation from the FDA, focuses on the rapid identification of common bloodstream infections associated with sepsis and is currently undergoing clinical studies. Additionally, HelixBind is developing the RaPID/Lyme Test to detect Lyme disease, supported by NIH grants. HelixBind primarily serves healthcare providers, including hospitals and clinical laboratories, that require accurate and timely diagnostic tools for managing bloodstream infections and sepsis. The company has a strong research background, backed by federal grants and recognition for its innovative approaches in medical diagnostics.

• Employees 29
• Founded 2013
• Annual Revenue $2000000
• Total Funding $18000000